|
|
|
|
|
26.03.26 - 08:03
|
Merck & Co schlägt schon wieder zu – Blockbuster-Chance (Der Aktionaer)
|
|
|
Der US-amerikanische Konzern Merck & Co will sich erneut im Bereich der Onkologie verstärken. Am gestrigen Mittwoch kündigte das Pharma-Unternehmen die geplante Übernahme von Terns Pharmaceuticals an. Merck & Co hat es dabei auf TERN-701 abgesehen, einem potenziellen Blockbuster zur Behandlung einer bestimmten Form von Leukämie....
|
|
|
|
|
|
|
|
|
25.03.26 - 12:24
|
Merck To Acquire Terns For $53.00/shr (AFX)
|
|
|
KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) and Terns Pharmaceuticals (TERN), a clinical-stage oncology company, announced that the companies have entered into a definitive agreement under which Merck......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.03.26 - 16:18
|
Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150 (24/7 Wall St.)
|
|
|
Merck & Co., Inc. (NYSE:MRK) has been on a strong recovery run, gaining 23% over the past year and 8% year-to-date, though the stock has pulled back some, now well below its 52-week high of $125.14. Most analysts hold measured views, with Street consensus sitting at $127.22. But Wells Fargo sees considerably more upside, raising ... Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150
The post Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150 appeared first on 24/7 Wall St.....
|
|
|
|
|
|